NEXALIS THERAPEUTICS LTD — Director's Dealing 2021

Aug 31, 2021

==> picture [380 x 126] intentionally omitted <==

ASX Announcement Change of Director’s Interest Notice

Melbourne, Australia, 1[st] September 2021: Australian medical-technology company Lifespot Health Ltd (ASX:LSH) (“Lifespot or the Company”) a developer of devices and systems that facilitates the management, diagnosis and evaluation of chronic disease, provides the attached Appendix 3Y for Company Director Darryl Davies.

The Company and Directors are committed to meeting their obligations not to trade in Company securities at times when they are, or may be perceived to be, in possession of market sensitive information concerning the Company that is not generally available to investors. While this trade occurred during a blackout period prior to lodgement of the Company’s Half Year Report, the Board considers that the Half Year results are in line with market expectation and did not include any inside material information that influenced Cannvalate Pty Ltd’s (Cannvalate) trading in Company securities. Mr. Davies is a Director of Cannvalate, however, he was not made aware, nor did he have any active involvement, in the share purchases being made on behalf of Cannvalate.

The Company notes that the purchase of shares occurred during a blackout period where exceptional circumstances must exist, and prior written approval must be granted to trade during such periods pursuant to the Company’s Securities Trading Policy. No such exceptional circumstances existed, and no approval was sought as Mr. Davies was unaware of the share purchases being made by Cannvalate. Cannvalate has taken steps to prevent such an event from occurring in future.

The Company also notes that this Appendix 3Y was not lodged within the requisite time frame due to the reasons discussed above. The Company took immediate steps to complete and lodge this Appendix 3Y as soon as the Company became aware of the matter.

The Board considers this an isolated incident for Mr. Davies and the Company will further review its current practices regarding trading in Company securities to ensure that all future trading occurs in strict compliance with the Trading Policy. No disciplinary or remedial action will be taken Lifespot, however, the Company will conduct further training and education in relation to its Trading Policy.

Lifespot currently has in place procedures whereby change in Directors’ interest and transactions in Company securities by the Directors are notified prior to the change occurring, to ensure that the Company can meet its disclosure obligations under listing rule 3.19A and disclose any changes to ASX within 5 business days. As a result of the of notification/approval request prior to the change not occurring these procedures will be reviewed and additional measures implemented. Such measures will include additional notification reminders of blackout periods and policy requirements to directors and reminders following approved trading that any unfilled orders must be removed.

The Company confirms it is in compliance with the ASX Listing Rules, in particular ASX Listing Rule 3.1.

Lifespot Health Limited (ACN 611 845 820) Suite 103, Level 1, 2 Queen St Melbourne 3000. phone 03 8395 5446.

==> picture [101 x 45] intentionally omitted <==

Authorised by the Board of Directors.

For further information: www.lifespot-health.com Nova Taylor Phone 03 8395 5446

Lifespot Health Limited (ACN 611 845 820) Suite 103, Level 1, 2 Queen St Melbourne 3000. Phone 03 8395 5446

Appendix 3Y Change of Director’s Interest Notice

Rule 3.19A.2

Appendix 3Y

Change of Director’s Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX’s property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity Lifespot Health Limited ACN 611 845 820

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Darryl Davies
Date of last notice	27/07/2021

Part 1 - Change of director’s relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should be disclosed in this part.

Direct or indirect interest	Indirect
Nature of indirect interest(including registered holder)Note: Provide details of the circumstances giving rise to the relevantinterest.	Cannvalate Pty Ltd
Date of change	11 - 24 August 2021
No. of securities held prior to change	32,194,676
Class	Ordinary fully paid shares (Share)
Number acquired	1,025,000
Number disposed	Nil
Value/ConsiderationNote: If consideration is non-cash, provide details and estimatedvaluation	$99,927
No. of securities held after change	33,219,676 Shares
Nature of changeExample: on-market trade, off-market trade, exercise of options, issueof securities under dividend reinvestment plan, participation in buy-back	On market Share purchases.

• See chapter 19 for defined terms.

Appendix 3Y Page 1

01/01/2011

Appendix 3Y Change of Director’s Interest Notice

Part 2 – Change of director’s interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.

Detail of contract	N/A
Nature of interest
Name of registered holder(if issued securities)
Date of change
No. and class of securities to whichinterest related prior to changeNote: Details are only required for a contract inrelation to which the interest has changed
Interest acquired
Interest disposed
Value/ConsiderationNote: If consideration is non-cash, provide detailsand an estimated valuation
Interest after change

Part 3 – + Closed period

Part 3 –+Closed period
Were the interests in the securities or contracts detailed abovetraded during a+closed period where prior written clearancewas required?	Yes
If so, was prior written clearance provided to allow the trade toproceed during this period?
If prior written clearance was provided, on what date was thisprovided?

• See chapter 19 for defined terms.

Appendix 3Y Page 2

01/01/2011